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Multiple primary malignant neoplasms are rare entities in the clinical setting, but represent 
an important issue in the clinical management of patients since they could be expression of a 
genetic predisposition to malignancy. A high resolution genome wide array CGH led us to identify 
the first case of a de novo constitutional deletion confined to the FBXW7 gene, a well known 
tumor suppressor, in a patient with a syndromic phenotype characterized by focal segmental 
glomerulosclerosis and multiple primary early/atypical onset tumors, including Hodgkin’s lymphoma, 
Wilms tumor and breast cancer. Other genetic defects may be associated with patient’s phenotype. 
In this light, constitutional mutations at BRCA1, BRCA2, TP53, PALB2 and WT1 genes were excluded 
by performing sequencing and MLPA analysis; similarly, we ruled out constitutional abnormalities at 
the imprinted 11p15 region by methylation specific -MLPA assay. Our observations sustain the role of 
FBXW7 as cancer predisposition gene and expand the spectrum of its possible associated diseases.
FBXW7 (F-box and WD repeat domain-containing 7) is a protein belonging to the SCF (SKP1-CUL1-F-box 
protein) E3 ligase complex, where it exerts a role of recognition and binding of target proteins for their 
degradation by the ubiquitin proteasome system (UPS). By UPS, FBXW7 regulates a network of proteins 
involved in cell division, cell growth and differentiation1. Several in vivo systems, mainly conditional 
knockout mouse models, evidenced its importance in tissue development as well as in cancer2. Indeed, 
it is believed that FBXW7 exerts a tumor suppressor (TS) activity by degrading oncogenic proteins, 
including cyclin E, MYC, JUN and Notch2.
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Moreover, the evidence that FBXW7 governs cellular apoptosis by ubiquitylation of MCL1, a 
pro-survival BCL2 family member, explains why altered FBXW7 activity enables cells to evade cell death 
programme3.
In consideration of the high number of targeted proteins, it is not surprising the wide spectrum of 
tumors harboring FBXW7 somatic mutations. Among these, mutations were most frequent in cholangi-
ocarcinoma and T-cell acute lymphoblastic leukemia, with a different mutation rate scored in other tum-
ors, possibly reflecting the tissue-specificity of its substrates1. However, unlike many TS genes, FBXW7 
does not follow a classic model of tumor suppression, as monoallelic alterations appear to be sufficient 
for cancer development. The two different “haploinsufficient”4 and “just enough”5 models have been 
proposed to explain its functional contribution to tumorigenesis.
FBXW7 is an issue of interest as well in the field of pharmacogenomics; it is in fact implicated in the 
response to specific chemotherapeutics and to mTOR inhibitors6,7.
To date only two cases of germline FBXW7 alterations have been reported in literature, arguing for 
its involvement in genetic predisposition to Wilms tumor (WT)8 and renal cell cancer (RCC)9. By iden-
tifying an additional case, which shows a peculiar phenotype but also shares some clinical features with 
the two previous reported patients, we endorse precedent findings and expand the spectrum of FBXW7 
potential related diseases.
Results
Clinical description. The patient is the first daughter of two unrelated Italian individuals and at age of 
34 was referred to oncological genetic counselling to evaluate the occurrence of a cancer predisposition 
syndrome. At the time of genetic counselling, her sister and mother were 32 and 60 years old, respec-
tively. No other cases of neoplasia were reported in the family, including in the paternal and maternal 
grandparents, but no information was available on health status of her father. The patient had a weight 
of 62 kg (75th percentile), a height of 152 cm (3th percentile), and an occipital frontal circumference of 
57,5 cm (> 97th percentile). At the age of 17, a nephrotic syndrome due to a primary focal segmental 
glomerulosclerosis (FSGS) was diagnosed and treated with steroid therapy, cyclophosphamide and cyclo-
sporin. The following year, during the immunosuppressive therapy, an Hodgkin’s lymphoma (nodular 
sclerosing type) stage IA (for right supraclavear node involvement) was identified and treated with radi-
otherapy of mediastinal, diaphragmatic and supraclavicular lymph nodes. At the age of 24, the patient 
underwent ovarian resection for a cystadenoma. At the age of 27, after 8 years of dialysis treatment due to 
the onset of chronic renal failure, she underwent kidney transplant in the left iliac fossa. A year later, the 
gallbladder was removed for gallstones and diverticulosis. Immunosuppressive therapy with cyclosporine 
and sirolimus (a mTOR inhibitor) was continued until the age of 32, when a Stage I WT of the naïve right 
kidney was diagnosed (triphasic nephroblastoma without anaplasia; at immunocytochemical analysis, 
WT1 was focally expressed at nuclear level by neoplastic cells) and treated by nephrectomy and adju-
vant chemotherapy with actinomycin D and vincristine. At the end of the adjuvant treatment, a mTOR 
inhibitor (everolimus) was maintained as unique immunosuppressant. At the age of 33, the patient was 
subjected to prophylactic nephrectomy of the residual left kidney due to the presence in the atrophic 
parenchyma of multiple perilobar nephrogenic rests (PLNRs) that were immunocytochemically reactive 
for WT1 at nuclear level. At the age of 34, the patient developed an invasive ductal carcinoma of the right 
breast (G2, ER and PgR positive, p185 3 + at biopsy), that was treated by neoadjuvant chemotherapy with 
carboplatin and taxol. No surgery was performed due to the identification of a bone metastases in the 
right humerus and characterized by HER2 amplification. Herceptin was added to the above mentioned 
chemotherapeutic agents and after the beginning of radiation therapy for bone metastases, capecitabine 
replaced carboplatin and taxol.
Investigations at constitutional level. After informed consent approved from the local Ethical 
Committee for Diagnostic and Research Purposes was obtained, TP53, BRCA1, BRCA2, PALB2 and WT1 
genes, which mutations could be possibly consistent with patient’s phenotype, were screened by Sanger 
sequencing and, to exclude large rearrangements, by Multiplex Ligation-dependent Probe Amplification 
assay (MLPA). No constitutional deleterious alterations were detected. Similarly, as constitutional defects 
at 11p15 involving the imprinted domain 1 cause non-syndromic WT10, we carried out methylation spe-
cific MLPA to determine copy number and methylation status at 11p15. Methylation appeared correctly 
assessed and microdeletions or duplications within the tested region were excluded.
Peripheral blood karyotyping revealed a normal female karyotype (46,XX). High resolution aCGH 
(Array Comparative Genomic Hybridization) 400 K of germline DNA led us to identify a constitutive 
heterozygous deletion of 157 kb mapping at 4q31.3 (Fig.  1A). The deletion spans between nucleotides 
153205202 and 153362047 (UCSC Genome Browser11, GRCh37/hg19 assembly), involves the DEAR 
pseudogene and almost the entire FBXW7 gene, sparing only the first exon of the two transcript variants 
(tv) at higher molecular weight (Fig. 1A, see tv1 and tv4).
No deletions of similar length were found in the DECIPHER database12. However, in this database 
are reported two de novo constitutive heterozygous deletions; the first, which spans 6.9 Mb and involves 
FBXW7 and 59 other genes, was found in a 27 years old 46,XX patient showing macrocephaly as the only 
clinical sign shared with our patient; the second spans 3.7 Mb including 32 genes, and was detected in a 
46,XX patient for whom clinical phenotype was not recorded.
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Two rare copy number losses affecting the FBXW7 locus, with a size similar to that of the deletion we 
found, are reported in the Database of Genomic Variant (data obtained from UCSC Genome Browser11 
GRCh37/hg19 assembly). The first is the merged variant nsv 516218 (6 supporting variants in a sample 
of 2,026 children mainly Caucasians or African-Americans), which completely spares the tv4 transcript 
variant; the second is the nsv 523798 (1 supporting variant observed in the same population of 2,026 
healthy children), variously affecting all the FBXW7 isoforms (Supplementary Fig. S1 online).
We studied the normal FBXW7 allele by PCR and Sanger sequencing and no deleterious mutations 
were found. Real-time PCR evidenced the decreased levels of FBXW7 expression in the patient-derived 
EBV lymphoblastoid cell line as compared to lymphoblastoid cell lines of ten normal controls with a ratio 
of 0,5:1 (Fig. 1B) that is consistent with the presence of an heterozygous deletion.
To ascertain if the deletion represented a de novo copy number variation (CNV) event, a high resolu-
tion aCGH analysis was performed on the mother’s constitutional DNA without any evidence of CNV at 
the FBXW7 locus. As DNA from the patient’s father was not available, the parental origin of the deleted 
allele was determined by genotyping the patient’s and her mother’s DNAs at four single nucleotide pol-
ymorphisms (SNPs) (rs2292743, rs1516822, rs6535847, rs7685296) mapping inside the deleted region. 
The haplotypes shown in Fig. 1C indicated the patient received a normal allele from her father, allowing 
to clarify that the deletion is a de novo event affecting the maternal allele.
Aiming at excluding a low level mosaicism in the mother, we designed a PCR assay to specifically 
amplify only the FBXW7 deleted allele. Long-range PCR using primers flanking the breakpoints was 
carried out on both the patient’s and mother’s DNAs. No PCR product was observed after amplification 
of maternal DNA. The PCR product obtained after amplification of patient’s DNA was sequenced to 
precisely redefine the breakpoints at nucleotide level (chr4:153197538-AAACAT-153365208, 167.7 kb). 
Using the patient’s DNA, we prepared serial dilutions mimicking mosaicism and ranging from 50% to 
0.1%. PCR product from the deleted allele was observed in each of the DNA dilutions providing evi-
dence, at least in peripheral B lymphocytes, of lack of low level mosaic deletion in the mother.
Figure 1. Identification of a FBXW7 intragenic deletion. (A) High-resolution aCGH profile showing the 
presence of a deletion affetting most of the FBXW7 gene coding region. (B) Relative gene expression analysis 
of FBXW7 mRNA in lymphoblastoid cells of the patient (blue) compared to a pull of ten lymphoblastoid 
cell lines from normal individuals (red), whose value was set to 1. ** = p < 0.01. (C) SNP haplotype analysis 
showed four informative SNPs, located in the deleted genomic region, allowing to establish the deletion’s 
maternal origin.
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Investigations at somatic level. WT tissue was the only available cancer lesion for further molecu-
lar analyses. A high resolution CGH array confirmed the known heterozygous FBXW7 germline deletion, 
and revealed additional copy number variations. Several small duplications, in the order of few Kbs and 
involving single genes, a wide duplication of 13 Mb localized in chromosome 20, and two heterozygous 
deletions of approximately 3 Mb mapping at 1p and 9q were detected. The log2 ratio profile of the X chro-
mosome near -1 was compatible with the loss of the entire chromosome in the tumor (Supplementary 
Table S1 online). The FBXW7 locus was investigated by PCR and Sanger sequencing and no deleterious 
mutations were detected, leading to exclude the presence of a second hit affecting the gene. Real-time 
PCR showed a decreased level of FBXW7 expression in WT tissue as compared to a normal renal tissue 
taken as reference with a ratio of 0,4:1 (Supplementary Fig. S2 online).
Besides PLNRs and marked signs of glomerulosclerosis, the left kidney showed papillary adenomas, 
microangiomas and cystic cavities, some of which characterized by microcalcifications and lined by cubic 
or flat cells (Fig. 2A). Strong nuclear immunoreactivity for TFE3 occurred in the cells lining cystic cav-
ities, while the other cells were negative (Fig. 2B). As immunoreactivity for TFE3 is a feature associated 
with Renal cell Carcinoma (RCC) characterized by the presence of TFE3 gene fusions13, an interphase 
FISH by using a break apart probe — designed to detect translocations involving the TFE3 gene at 
Xp11.2— was performed on formalin-fixed, paraffin-embedded tissues (FFPE) on the area of the cysts 
immunoreactive for TFE3 of left atrophic kidney. No evidence of a TFE3 translocation was found; how-
ever, a condition of heterogeneity characterized by normal cells mixed with cells with an increased TFE3 
copy numbers (three to five fused signals) was detected (Fig. 2C). A following interphase dual color FISH 
by using centromeric probes for X and 18 chromosomes displayed that the increased TFE3 copy number 
in the immunoreactive cystic epithelium is related to X-chromosome aneuploidy (Fig. 2D). Indeed, while 
in the surrounding tissue a ratio near 1 between X/18 chromosome signals was scored, inside the cystic 
lesion the ratio raised to 1,32 (3:2), with a total 35% of nuclei showing 3 or more X chromosome signals 
and a ratio between X/18 chromosome signals different and major than 1.
Discussion
Genetic susceptibility to cancer can result from a wide range of constitutive genetic lesions, including 
rare Copy Number Variations (CNVs) encompassing cancer genes. The search for CNVs in patients 
Figure 2. (A) Cystic lesions characterized by a cubic or flat epithelium. (B) Immunohistochemical analysis 
for TFE3. (C) TFE3 Break Apart probe FISH on interphase nuclei of the cystic epithelium positive for 
TFE3 immunostaining. Three cells each with three yellow fused signals, due to lack of traslocation of the 5′ 
TFE3 red probe from 3′ TFE3 green probe, show each a duplication of a TFE3 allele. (D) Dual color FISH 
with chromosome X (green) and 18 (red) centromeric probes on interphase nuclei of the cystic epithelium 
positive for TFE3 immunostaining. Most of the cells show two red chromosome 18 centromeric signals and 
two to four green X chromosome centromeric signals.
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with a clinical picture suggestive of an inherited cancer predisposition syndrome can lead to disclose the 
alteration causative of the cancer susceptibility14.
We detected by aCGH the first case of germline deletion confined to the FBXW7 gene in a patient 
with a syndromic phenotype characterized by small stature, relative-to-height macrocephaly, focal seg-
mental glomerulosclerosis (FSGS) and multiple, early/atypical onset primitive tumors. The lack of a sec-
ond hit of FBXW7 in WT tissue supports evidences for its haploinsufficiency, but FBXW7 expression 
levels in WT as compared to a normal kidney showed a ratio (0,4:1) with a slight deviation from the 0,5:1 
ratio expected in a clear haploinsufficient status at RNA level. This result can depend on several factors, 
including a physiological variability of FBXW7 expression between two RNA specimens, and prevented 
to clarify the functional contribution of FBXW7 to tumorigenesis, but is in line with the notion that 
FBXW7 is not a classic tumor suppressor gene4,5.
We propose that the identified deletion would have caused increased cancer susceptibility. Although 
copy number losses affecting only FBXW7 locus are reported in the DGV, these nsv-s can be classified by 
frequency as rare (nsv 516218, < 1% population frequency) or very rare (nsv 523798, < 0,1% population 
frequency) variants, indeed potentially pathogenetic14. The lack of copy number losses in healthy adult 
population, but not in children, corroborates the hypothesis that the deletion described in our study 
could predispose to disease in adult life.
The case-patient we studied developed a WT of the right kidney at the age of 32 years old. WT is the 
most common renal tumor of childhood, occurring rarely in adults, and it can be related to germline 
mutations causing peculiar genetic syndromes or non-syndromic conditions predisposing to its develop-
ment15. Among the different involved genes15, WT1 germline mutations give rise to isolated WT, isolated 
forms of FSGS, and to two rare syndromes characterized by the association of male pseudohermaphro-
dism in 46,XY karyotype with FSGS and gonadoblastoma (Frasier syndrome), or with diffuse mesangial 
sclerosis and WT (Denys-Drash syndrome), reflecting the complex role of WT1 in cancer and embryonic 
urogenital development16. The occurrence of diffuse PLNRs in the controlateral kidney represents an 
additional indication for the presence of a genetic defect conferring a predisposition to cancer. PLNRs, 
which are abnormally persistent foci of embryonic kidney cells considered to be benign WT precursors, 
are mainly seen in sporadic tumors and in overgrowth syndromes (idiopathic hemihypertrophy and 
Beckwith-Wiedemann syndrome), both associated with genetic/epigenetic dysregulation at 11p15 lead-
ing to overexpression of IGF-II17. Also constitutional defects at 11p15 involving the imprinted domain 
1 cause nonsyndromic WT10. The patient we studied had a normal 46,XX karyotype and tested negative 
for WT1 germline mutations and for 11p15 constitutional abnormalities.
Other known candidate cancer genes, which mutations could be consistent with patient’s phenotype, 
exist. Specifically, TP53 is the only one which mutations could be strictly consistent with patient’s pheno-
type; it should be however noted that the TP53 associated tumor spectrum generally includes soft-tissue 
and bone sarcomas. Mutations in BRCA1, BRCA2, and PALB2 could be implicated because of the young 
age of onset of breast cancer; while BRCA1 mutations are not associated with WT or Hodgkin’s lym-
phoma (HL), bi-allelic mutations of BRCA2 and PALB2 cause Fanconi Anemia type D1 and Fanconi 
anemia type N, respectively, of which WT is an associated clinical feature. As no constitutional delete-
rious mutations were detected in TP53, BRCA1, BRCA2 and PALB2, we excluded all the known genetic 
syndromes consistent with the overall phenotype.
The involvement of FBXW7 as a novel WT gene has already been advocated by Williams et al. who 
identified FBXW7 somatic alterations in about 4% of sporadic WTs8. Among the tested cases, the authors 
also identified one patient carrying a FBXW7 heterozygous germline mutation (c.45_46insCCT) impair-
ing only the α -isoform of the transcripts, but the coexistence of another germline mutation in WT1 
in the patient hampered any consideration about the contribution of the FBXW7 alteration to tumor 
predisposition. Moreover, WT and FSGS might not represent two coincident events, as FBXW7 is a 
negative regulator of Notch12, and sustained Notch activation is a known mechanism in the pathogenesis 
of FSGS18.
We must however take into account that our patient presented with FSGS closely followed by HL. 
Although association between nephrotic syndrome and malignancy is known to exist, the specific com-
bination of FSGS and HL is reported as a rare event in literature, and the biological mechanism linking 
the two diseases has not yet been clarified19. We can only speculate that, if we look at FSGS as a parane-
oplastic glomerulopathy secondary to an originally hidden HL, we would expect an improvement of the 
renal condition in parallel with the remission of HL.
With regard to the relationship between FBXW7 and HL development, less we can infer from the 
literature; we know of the involvement of FBXW7 in several forms of acute leukemias20, mainly T-cell 
(T-ALL), as also demonstrated by conditional FBXW7–/– knockout models in bone marrow and in 
T cell lineage developing T-ALL and, thymic lymphoma, respectively2. Moreover, a FBXW7 SNP was 
demonstrated to act as germline modifier of tumor susceptibility, as it influences the radiation-induced 
lymphomas development in a p53-dependent manner21.
The patient, who developed an early-onset breast cancer, tested negative for mutation screening in 
the most common breast cancer predisposition genes. The evidences that i) FBXW7 +/– heterozygous 
mice show susceptibility to radiation induced tumorigenesis2, and that ii) a polymorphism of FBXW7 
may be a risk factor for breast cancer development22 let us to include breast cancer in the spectrum of 
neoplasia related to the FBXW7 deletion in this patient. Indeed, if it is true that breast cancer is the most 
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common therapy-related subsequent neoplasia after HL, with a clearly demonstrated role for irradiation, 
it is also true that individual constitutional variations of genes involved in DNA stability (as reported 
for FBXW723) can modulate the risk of second primary cancers after exposure to DNA-damaging agents 
such as radiations and chemotherapy24.
Interestingly, patient’s left kidney showed, besides PLNRs, some cystic lesions characterized by an 
epithelium reactive for TFE3, which is a marker for a specific RCC subtype, primarily occurring in chil-
dren and young adults and characterized by Xp11.2 translocations leading to different type of TFE3 gene 
fusions13. By FISH experiments, we demonstrated that immunoreactivity is probably related to a copy 
number gain of TFE3 due to aneuploidy of X chromosome, as yet described in other sporadic cases25. 
This lead us to deduce that TFE3 is not silenced at renal level by inactivation of additional X chromo-
somes. It is difficult to explain the significance of this finding, and if these cystic lesions may represent 
very early cancer lesions, but this observation gains in significance in the light of the case described by 
Kuiper et al. who identified in an adult patient affected by a RCC a familial constitutional translocation 
t(3;4)(q21;q31) disrupting the FBXW7 gene at 4q but no genes at 3q9.
Unlike our patient, no peculiar clinical features other than a single cancer were described in the two 
cases studied by Kuiper and Williams, the only ones reporting a FBXW7 germline alteration. Several 
reasons may explain this discrepancy: i) differences in the deepening of clinical investigations, ii) types of 
FBXW7 molecular defect in the patients, their individual genetic background and variable penetrance of 
the mutations, and iii) use or combination of different chemotherapeutic treatments based on anti-cancer 
drugs, or immunosuppressants and inhibitors of mTOR, that is a target of FBXW77.
In conclusion, we extensively characterized the clinical phenotypes of a patient harboring a de novo 
germline deletion in FBXW7, expanding the spectrum of signs and diseases possibly associated to this 
gene. Also because FBXW7 is involved in the response to immunosuppressive7 and chemotherapeutic 
agents6, germline FBXW7 genetic testing should be considered in individuals affected with atypical WT 
and early RCC where a complex clinical picture exists.
Methods
Mutation screening. All the investigations were carried out after that informed consent for Diagnostic 
and Research Purposes approved by the Ethics Committee of Fondazione IRCCS Istituto Nazionale dei 
Tumori was obtained. The methods were carried out in accordance with the approved guidelines.
For the detection of constitutional mutations in TP53, BRCA1, BRCA2, PALB2, WT1 and FBXW7, 
genomic DNA was extracted from whole blood using Qiagen DNeasy Blood & Tissue Kit (Qiagen). After 
amplification, Sanger sequencing of the entire coding region and splice sites of the genes were performed. 
Moreover, Multiplex Ligation-dependent Probe Amplification assay (SALSA MLPA kit—MRC-Holland) 
for all the cited genes, with the exception of FBXW7, was performed in accordance with the manufac-
turer’s instructions. For the screening of FBXW7 somatic mutations, genomic DNA was extracted from 
FFPE WT by QIAamp DNA FFPE Tissue Kit (Qiagen). Coding exons and splice sites belonging to 
the four alternative transcripts ( tv 1, 2, 3, 4; RefSeq: NM_033632.3, NM_018315.4, NM_001013415.1, 
NM_001257069.1, respectively) were amplified and sequenced as above described (see Supplementary 
Table S2 online for primers and conditions).
MS-MLPA-technique. The MCR-Holland kit, ME-30 RSS_BWS (MRC Holland, Amsterdam, The 
Netherlands) was used according to the kit instructions. DNAs were extracted from the patient-derived 
EBV lymphoblastoid cell line, and from normal EBV lymphoblastoid cell lines used as controls. DNAs 
with and without digestion with the methylation sensitive Hha I enzyme were parallely processed to 
detect both methylation dysregulation and copy number variation. Data analysis was carried on by the 
Coffalyzer DB software (Software version: v131211) providing data related to copy number variants and 
to the methylation status. The latter is defined by the ratio of unmethylated versus methylated DNA, 
referring each test sample to positive and negative references.
High-resolution array Comparative Genomic Hybridization (CGH) analysis. Genomic DNA 
was extracted from whole blood using the GenElute Blood Genomic DNA kit (Sigma-Aldrich, St. Louis, 
MO) in accordance with the manufacturer’s instructions. Wilm’s tumor DNA was extracted from FFPE 
sample, based on the method described by van Beers et al.26 using the Qiagen DNeasy Blood & Tissue 
Kit (Qiagen). The genome scan was performed using the Human Genome CGH Microarray Kit 400 K for 
blood, and 244 K for WT (Agilent Technologies, Santa Clara, CA). From both test and normal reference 
samples, 700 ng of DNA were processed according to the manufacturer’s instructions.
Quantitative FBXW7 mRNA expression analysis. FBXW7 mRNA expression levels were deter-
mined by qPCR on RNA of the patient and ten controls, isolated from lymphoblastoid cells and 
reverse-transcribed using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster 
City, CA). Quantitative real-time RT-PCR, based on the TaqMan methodology, were performed using 
an ABI PRISM 7700 Sequence Detection System (Applied Biosystems). The amounts of FBXW7 mRNA 
were calculated using the 2-∆∆Ct method, with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
and beta-actin (ACTB) as the endogenous-normalizing genes. All assays were provided by Applied 
Biosystems (TaqMan Gene Expression Assays: ID# Hs00217794_m1 FBXW7; Hs99999905_m1 GAPDH; 
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Hs99999903_m1 ACTB). Real-time data were analysed using the RQ Manager 1.2 software (Applied 
Biosystems). Statistical analysis was performed by two-tailed Student’s t test and significance was con-
sidered at p < 0.01.
The same method was applied to quantify FBXW7 expression levels in WT as compared to a normal 
kidney. RNAs were obtained from five macrodissected FFPE tissue slice of WT and from a normal FFPE 
renal specimen by using the RecoverAll™ Total Nucleic Acid Isolation Kit (Life Technologies). A pre 
amplification of cDNA from FFPE samples was performed prior to real time PCR by using the PreAmp 
kit (Applied Biosystems). Beta-actin (ACTB) and hydroxymethylbilane synthase (HMBS) were used as 
the endogenous-normalizing genes (TaqMan Gene Expression Assays: ID# Hs00609297_m1 HMBS).
SNP Haplotype Analysis. To establish the parental origin of the deleted allele, sequence-specific 
PCR was carried out both in patient and patient’s mother. Oligonucleotides and amplification conditions 
used to amplify four informative SNPs are shown in the Supplementary Table S3 online.
PCRs were performed using the AmpliTaq Gold® kit (Applied Biosystems) and the resulting frag-
ments were sequenced using the Big Dye® Terminator v.3.1 Cycle Sequencing kit (Applied Biosystems). 
Sequences were then aligned to the human reference genome sequence (human genome GRCh37/hg19 
assembly), and analysed with the ChromasPro 1.5 software (Technelysium Pty Ltd., Tewantin QLD, 
Australia).
Amplification of the deletion junction fragment and assessment of a possible maternal 
mosaicism. To localize the deletion breakpoints at nucleotide level in the patient, long-range PCR 
(LR-PCR) was carried out using the TaKaRa LA TaqTM kit (Takara Bio Inc., Shiga, Japan). The result-
ing junction fragment was redefine performing sequence-specific PCR using the AmpliTaq Gold® kit 
(Applied Biosystems). Primer pairs and amplification conditions used to amplify the deletion breakpoint 
are shown in the Supplementary Table S4 online.
Sequencing was performed as described before. To assess a possible low level maternal mosaicism, 
the same PCR was performed in the mother. Serial dilutions of the patient’s DNA with a reference DNA 
corresponding to a mosaicism of the deletion of 50%, 25%, 12.5%, 5%, 2.5%, 1%, 0.5%, 0.25%, 0.1% were 
carried out to evaluate the PCR sensibility.
Immunohistochemistry for TFE3 detection. For immunocytochemical studies, 5 μ m-thick sec-
tions were processed in an automated Ventana BenchMark IHC/ISH instrument using XT ultraview 
DAB v3 protocols (Ventana System, Tucson, AZ). A rabbit monoclonal anti-TFE3 antibody (MRQ-37, 
Cell Marque) was applied.
Interphase FISH for TFE3 detection. FISH analysis was performed on 4 μ m FFPE tissue sections 
using TFE3 (Xp11.2) Break Apart probe (Poseidon) and CEP18, X, Y-alpha satellite probe (Vysis).
Sections were baked o/n at 60 °C, deparaffinized by soaking slides in xylene and then rehydrated. They 
were heated in pre-treatment solution at 95 °C for 20 minutes, digested with pepsin at 37 °C for 40 min-
utes and dehydrated. Finally samples were denatured according to the probe manufacturer’s instructions, 
incubated o/n at 37 °C in a humidified chamber, washed in post-hybridization buffers and counterstained 
with DAPI/Antifade.
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